文献速递糖尿病

结合珠蛋白表型与强化血糖控制对2型糖尿病患者冠心病风险降低的影响:ADVANCE研究

Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study.
PubMed 文献 · Diabetes Care · 2024-01-01

在ADVANCE生物标志物病例队列研究中,按结合珠蛋白表型分层分析强化血糖控制(HbA1c目标≤6.5%)与标准治疗对主要冠心病事件的影响;总体无显著关联,但在无既往心血管病的Hp2-2表型者中强化治疗与较低冠心病风险相关(HR 0.84,95%CI 0.63-1.14;交互P=0.27)。

要点

  • 总体而言,强化血糖控制与标准治疗相比,主要冠心病事件风险在有无Hp2-2表型者中均无显著差异。
  • 在无既往心血管病的Hp2-2表型者中,强化治疗与较低冠心病风险相关(HR 0.47,95%CI 0.29-0.76)。
  • Hp2-2表型与强化治疗的交互作用总体不显著(P=0.27),但在无既往心血管病亚组中显著(P=0.01)。

核心结论

  • 研究提示,在无既往心血管病的ADVANCE参与者中,Hp2-2表型者接受强化血糖控制可能有助于预防主要冠心病事件,与强化血糖控制可能对部分Hp2-2表型者有益的假设一致。

研究设计与样本

  • ADVANCE生物标志物病例队列研究,测量可得样本的结合珠蛋白表型。
  • 采用加权多变量校正Cox回归模型,分别评估有无Hp2-2表型者中强化血糖控制(HbA1c目标≤6.5%)与标准治疗(基于当地指南)和主要冠心病事件的关系。
  • Hp2-2表型者n=1,327,无Hp2-2表型者n=2,077。
  • 预设按性别、种族、既往心血管病、糖尿病病程和HDL胆固醇进行分层分析。

主要发现

  • 总体分析中,强化血糖控制与标准治疗相比,无Hp2-2表型者主要冠心病事件风险HR为1.04(95%CI 0.82-1.32),Hp2-2表型者为0.84(95%CI 0.63-1.14),交互作用P=0.27,均未达统计学显著。
  • 在无既往心血管病的Hp2-2表型者中,强化治疗与较低冠心病风险相关(HR 0.47,95%CI 0.29-0.76),交互作用P=0.01。

关键数值与推荐

  • 强化血糖控制定义为HbA1c目标≤6.5%。
  • 标准治疗基于当地指南。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants with the haptoglobin (Hp)2-2 phenotype but not in participants without the Hp2-2 phenotype. It is unknown whether and how these results translate across different demographic/clinical characteristics and treatment strategies. RESEARCH DESIGN AND METHODS: Haptoglobin phenotype was measured in available samples from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) biomarker case-cohort study. Weighted multivariable-adjusted Cox regression models were used to evaluate the association between intensive glycemic control (HbA1c target of ≤6.5%) versus standard therapy (based on local guidelines) and major CAD events among participants with (n = 1,327) and without (n = 2,077) the Hp2-2 phenotype separately and within prespecified stratifications by sex, race, previous cardiovascular disease (CVD), diabetes duration, and HDL-cholesterol. RESULTS: While the hazard ratios (HRs) were in the hypothesized differing directions, compared with standard therapy, intensive glycemic control was not significantly associated with risk of CAD events among participants without (1.04, 95% CI 0.82-1.32) or with (0.84, 0.63-1.14, Pinteraction = 0.27) the Hp2-2 phenotype overall. Intensive therapy was associated with lower CAD risk among participants with the Hp2-2 phenotype who had no previous CVD (0.47, 0.29-0.76, Pinteraction = 0.01). CONCLUSIONS: Our findings suggest that intensive glycemic control contributes to the prevention of major CAD events among ADVANCE participants with the Hp2-2 phenotype and no previous CVD and are in alignment with our hypothesis that intensive glycemic control may be beneficial in a subset of people with the Hp2-2 phenotype.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Cahill LE, Warren RA, Carew AS, et al. Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study. Diabetes Care. 2024. PMID: 38484336. doi:10.2337/dc23-2165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。